ABSTRACT A significant proportion of COVID-19 patients show evidence of
hyperinflammation (HI), of which secondary haemophagocytic lymphohistiocytosis (sHLH) is …

The clinical manifestation of moderate to severe coronavirus disease 2019 (COVID-19) has
parallels to secondary hemophagocytic lymphohistiocytosis (HLH) both clinically and based …

Discussion This case supports the notion that a distinct inflammatory syndrome
accompanies COVID-19 that may be secondary HLH. A proinflammatory cytokine profile …

Background COVID-19, a disease caused by the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), commonly presents as fever, cough, dyspnea, and myalgia or …

Background Secondary haemophagocytic lymphohistiocytosis (sHLH) is characterised by a
hyper activation of immune system that leads to multiorgan failure. It is suggested that …

Background Secondary hemophagocytic lymphohistiocytosis (sHLH) is a life-threatening
hyperinflammatory event and a fatal complication of viral infections. Whether sHLH may also …

Interventions: A treatment regimen of methylprednisolone, pentaglobin, and anakinra was
developed and administered. Outcomes: One patient survived the ICU stay. Two other …

Severe COVID-19 associated respiratory failure, poses the one challenge of our days.
Assessment and treatment of COVID-19 associated hyperinflammation may be key to …

The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), has resulted in significant morbidity and mortality …

Objective Coronavirus disease 2019 (COVID-19) is associated with diffuse lung injury that
can progress to acute respiratory distress syndrome, multisystem-organ failure, and death …